-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on Denali Therapeutics, Raises Price Target to $36

Benzinga·07/23/2026 18:04:21
Listen to the news
Morgan Stanley analyst Matthew Harrison maintains Denali Therapeutics (NASDAQ:DNLI) with a Overweight and raises the price target from $35 to $36.